A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer

Trial Profile

A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2016 Status changed from recruiting to discontinued.
    • 13 Oct 2015 According to the ClinicalTrials.gov record, chemotherapy regimen has been changed from FOLFIRINOX to gemcitabine, nab-paclitaxel and capecitabine; planned patient number changed from 288 to 346.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top